European Journal of Heart Failure最新文献

{"title":"The CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.","authors":"Maja Ivanovski,Miha Mrak,Anja Zupan Mežnar,Matevž Jan,Catalin Pestrea,Sandro Brusich,Peter Bogyi,Sebastiaan Dhont,Zrinka Jurišić,Vassil Traykov,Borka Pezo Nikolić,Wilfried Mullens,David Žižek","doi":"10.1002/ejhf.70013","DOIUrl":"https://doi.org/10.1002/ejhf.70013","url":null,"abstract":"AIMSThere is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.METHODSThis study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS. Participants will be randomized 1:1 to CSP or BVP with subsequent AVNA and followed for at least 24 months. The primary endpoint is the change in LVEF after 6 months. Secondary endpoints will include time to the first occurrence of worsening HF or cardiovascular death and its individual components, total number of HF hospitalizations, change in quality of life, N-terminal pro-B-type natriuretic peptide, 6-min walk test distance, and safety outcomes.CONCLUSIONSThe CONDUCT-AF trial will provide critical insights into the optimal pacing modality for patients with HF and refractory AF undergoing AVNA. Recruitment is expected to conclude in 2025, with the first study results anticipated in 2026.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"26 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to the letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'.","authors":"Tibor Kempf,Jan Fuge,Johann Bauersachs","doi":"10.1002/ejhf.70029","DOIUrl":"https://doi.org/10.1002/ejhf.70029","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"15 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding the article 'Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction'.","authors":"Hui-Chin Chang,Shuo-Yan Gau","doi":"10.1002/ejhf.70045","DOIUrl":"https://doi.org/10.1002/ejhf.70045","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"57 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.","authors":"Luis Eduardo Echeverria,Edimar Bocchi,Caroline Demacq,Pedro Gabriel Melo de Barros E Silva,Lu-May Chiang,Sarfaraz Sayyed,Lucas Petri Damiani,Lilian Mazza Barbosa,Remo Holanda de Mendonça Furtado,Carlos A Morillo,Ruben Kevorkian,Felix Ramires,Maria Cecilia Bahit,Adolfo Chavez-Mendoza,José Antonio Magaña-Serrano,Justo Carbajales,Wilson Oliveira Junior,Israel Molina,Arguinaldo F Freitas Junior,Maria da Consolaçao Moreira,Adegil Henrique Silva,Telemaco Silva Junior,Wladimir Saporito,José Francisco Kerr Saraiva,Claudio Gimpelewicz,John J V McMurray,Renato Delascio Lopes, ","doi":"10.1002/ejhf.70026","DOIUrl":"https://doi.org/10.1002/ejhf.70026","url":null,"abstract":"AIMSThe PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.METHODS AND RESULTSPARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%. Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid). Enrolled participants (mean age: 64.2 years, 42.0% women) had a baseline LVEF of 29.8% (NYHA class II: 61.7%; NHYA class III/IV: 38.2%). History included hypertension (40.5%), atrial fibrillation/flutter (32.5%), ventricular arrhythmia (24.7%) and stroke (12.5%). The majority of patients had cardiac conduction abnormalities and 46.0% had conventional pacemaker, cardiac resynchronization therapy or implantable cardioverter-defibrillator. Mean systolic blood pressure was 118 mmHg, and median NT-proBNP level was 1730 pg/ml.CONCLUSIONSBaseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"30 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'.","authors":"Peng Sun","doi":"10.1002/ejhf.70024","DOIUrl":"https://doi.org/10.1002/ejhf.70024","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"24 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter regarding the article 'Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial'.","authors":"Zongyu Yang,Liqiu Kou,Songjie Liao","doi":"10.1002/ejhf.70039","DOIUrl":"https://doi.org/10.1002/ejhf.70039","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"28 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles","authors":"Anne Marie Reimer Jensen, James C. Ross, Victoria Arthur, Michael E. Hall, Kunihiro Matsushita, Brandon Lennep, Pamela L. Lutsey, Tor Biering‐Sørensen, Amil M. Shah","doi":"10.1002/ejhf.70015","DOIUrl":"https://doi.org/10.1002/ejhf.70015","url":null,"abstract":"AimsTo jointly model longitudinal measures of left ventricular ejection fraction (LVEF) and E/A ratio in late‐life, and to assess whether predicted trajectory membership is associated with heart failure risk.Methods and resultsUsing a Bayesian non‐parametric trajectory approach, trajectories were modelled among 747 Jackson Heart Study participants who underwent ≥2 echocardiograms in 2000–2004 (age 65 ± 5 years), 2011–2013 (75 ± 5), and 2018–2019 (81 ± 5). Using the resulting model, we predicted trajectory membership for 4419 distinct Atherosclerosis Risk in Communities (ARIC) study participants based on single time‐point measures of LVEF and E/A ratio (age 75 ± 5 years; ‘testing cohort’). Multivariable Cox models assessed the relationship between predicted trajectory and incident heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF). We evaluated associations of 4877 plasma proteins (SOMAscan) with predicted trajectory and performed Mendelian randomization to assess causal effects on LVEF and volume. Six trajectories were identified: pink (prevalence 50%) and light green (17%) – increasing LVEF, decreasing E/A ratio with age; red (22%) – no increase in LVEF; dark green (4%) – declining LVEF; orange (2%) – steeply declining LVEF, rising E/A ratio; and blue (4%) – rising E/A ratio despite increasing LVEF. In the testing cohort, red and dark green associated with HFrEF alone, blue with HFpEF alone, and orange with both compared to pink. Trajectory membership provided incremental value in predicting heart failure and HFpEF. Mendelian randomization identified potential causal effects of 13 trajectory‐associated proteins on LVEF and volume.ConclusionsBayesian non‐parametric modelling identifies cardiac function trajectories differentially associated with HFpEF and HFrEF and holds promise to improve risk prediction and enable therapeutic target discovery.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"66 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of wild‐type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study","authors":"Alberto Aimo, Giuseppe Vergaro, Maria Concetta Pastore, Daniela Tomasoni, Vincenzo Castiglione, Riccardo Saro, Elisa Zaro, Antonio Maria Sammartino, Elisa Giacomin, Matteo Serenelli, Alberto Cipriani, Aldostefano Porcari, Andrea Di Lenarda, Marco Metra, Gianfranco Sinagra, Matteo Cameli, Marco Merlo, Michele Emdin","doi":"10.1002/ejhf.70030","DOIUrl":"https://doi.org/10.1002/ejhf.70030","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"38 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144928251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.","authors":"Karina V Bunting, Asgher Champsi, Simrat K Gill, Khalil Saadeh, A John Camm, Mary Stanbury, Sandra Haynes, Jonathon N Townend, Richard P Steeds, Dipak Kotecha","doi":"10.1002/ejhf.70022","DOIUrl":"https://doi.org/10.1002/ejhf.70022","url":null,"abstract":"<p><strong>Aims: </strong>To compare the effect of digoxin versus beta-blockers on left ventricular function, in patients with permanent atrial fibrillation (AF) and symptoms of heart failure within the RATE-AF randomized trial.</p><p><strong>Methods and results: </strong>Blinded echocardiograms were performed at baseline and 12-month follow-up using a pre-defined imaging protocol and the index-beat approach. The change in systolic and diastolic function was assessed, stratified by left ventricular ejection fraction (LVEF). Overall, 145 patients completed follow-up, with median age 75 years (interquartile range 69-82) and 44% women. In 119 patients with baseline LVEF ≥50%, a significantly greater improvement in systolic function was noted in patients randomized to low-dose digoxin versus beta-blockers: adjusted mean difference for LVEF 2.3% (95% confidence interval [CI] 0.3-4.2; p = 0.021), s' 1.1 cm/s (95% CI 1.0-1.2; p = 0.001) and stroke volume 6.5 ml (95% CI 0.4-12.6; p = 0.037), with no difference in global longitudinal strain (p = 0.11) or any diastolic parameters. There were no significant differences between groups for patients with LVEF 40-49% and <40%. Digoxin reduced N-terminal pro-B-type natriuretic peptide compared to beta-blockers (geometric mean difference 0.77; 95% CI 0.64-0.92; p = 0.004), improved New York Heart Association functional class (odds ratio [OR] 11.3, 95% CI 4.3-29.8; p < 0.001) and modified European Heart Rhythm Association arrhythmia symptom class (OR 4.91, 95% CI 2.36-10.23; p < 0.001), with substantially less adverse events (incident rate ratio 0.21, 95% CI 0.13-0.31; p < 0.001). There were no interactions between treatment effects and baseline LVEF for these outcomes (interaction p = 0.62, 0.49, 0.07 and 0.13, respectively).</p><p><strong>Conclusions: </strong>Low-dose digoxin in patients with symptoms of heart failure, preserved LVEF and permanent AF leads to a significantly greater improvement in systolic function compared to treatment with beta-blockers.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher hospital volume is associated with lower mortality for patients with cardiogenic shock and mechanical circulatory support","authors":"Angela Dettling, Caroline Kellner, Jonas Sundermeyer, Benedikt N. Beer, Lisa Besch, Marvin Kriz, Stefan Kluge, Paulus Kirchhof, Stefan Blankenberg, Benedikt Schrage","doi":"10.1002/ejhf.70025","DOIUrl":"https://doi.org/10.1002/ejhf.70025","url":null,"abstract":"AimsMortality for cardiogenic shock (CS) remains high. To improve outcomes, centralization of treatment in specialized centres, especially those with expertise in mechanical circulatory support (MCS), has been recommended. High‐volume centres may be able to provide standardized, better care. We analysed associations between centre volume and outcomes in Germany, a large country with multiple types of CS centres.Methods and resultsBased on data from all CS patients treated in Germany from 2017–2021, the association between annual CS/MCS hospital volume and in‐hospital mortality was assessed using adjusted Cox‐regression, and spline plots were used to assess case thresholds. Overall, 220 223 CS patients underwent treatment at 1232 hospitals; 435/1232 (35%) of these performed MCS therapy, although only few hospitals (60/435, 14%) performed &gt;25 MCS cases per year on average. Treatment at hospitals with a higher annual volume of CS and MCS cases was associated with a significantly lower mortality risk as compared to hospitals with a lower volume (upper third vs. lower two‐thirds; CS: hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.91–0.94; <jats:italic>p</jats:italic> &lt; 0.001; MCS: HR 0.80, 95% CI 0.76–0.84; <jats:italic>p</jats:italic> &lt; 0.001). These associations were continuous without a detectable ceiling effect, with spline plots suggesting case thresholds of at least 90 CS cases/25 MCS cases per year.ConclusionsCare for patients with CS treated with and without MCS is associated with lower in‐hospital mortality in hospitals that manage high volumes of CS and MCS. This analysis indicates that centralization of CS care in specialized centres treating high volumes of patients with CS and MCS might improve outcomes.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"9 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}